本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东方金融控股集团股份有限公司（以下简称"公司"）十届董事会第十 三次会议于 2025 年 7 月 8 日以通讯方式召开，会议应参加表决董事 7 人，实参 加表决董事 7 人。会议召开符合《公司法》和《公司章程》的有关规定，所做决 议合法有效。 | 证券代码：600120 | 证券简称：浙江东方 | | | 公告编号：2025-035 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 会议审议并通过了如下议案： 浙江东方金融控股集团股份有限公司 一、关于选举公司董事长的议案 十届董事会第十三次会议决议公告 表决结果：同意票 7 票，反对票 ...

Group 1 - The company announced the resignation of its chairman, Jin Zhaoping, due to organizational arrangements [1] - Wang Zhengjia has been elected as the new chairman, with a term starting from the date of approval until the end of the company's tenth board term [1] - Jin Zhaoping did not hold any shares in the company and has completed the handover process [1]

Core Viewpoint - The discussion emphasizes the importance of patience in the relationship between General Partners (GPs) and Limited Partners (LPs) in the current investment climate, highlighting the need for mutual understanding and collaboration to navigate the challenges of the venture capital industry [2][5][21]. Group 1: Industry Trends - The 19th China Fund Partners Conference gathered key players in the investment industry to discuss the latest trends and dynamics in the LP market, focusing on the new cycle of venture capital [2][5]. - The current investment environment is characterized by a cooling period, necessitating GPs and LPs to work closely together and support each other [5][9]. Group 2: Company Insights - Dongfang Jiafu, a mixed-ownership technology investment institution, manages over 16 billion RMB in funds and focuses on early to mid-stage investments in sectors like intelligent manufacturing and life sciences [6]. - Shanghai Science and Technology Innovation Fund, established in 2017, has a management scale of 170 billion RMB and has invested in over 2,500 projects, with 159 companies listed [7]. - Yicun Capital, founded in 2015, has a management scale exceeding 300 billion RMB and focuses on sectors such as healthcare and artificial intelligence, with a strong emphasis on mergers and acquisitions [8]. Group 3: GP and LP Relationship Dynamics - The relationship between GPs and LPs has evolved, with LPs becoming more proactive and demanding, leading to a need for GPs to adapt their investment strategies accordingly [9][10]. - The collaboration between GPs and LPs is increasingly seen as a partnership, requiring shared goals and mutual understanding to achieve long-term success [14][20]. - The market has seen a significant shift, with state-owned LPs now accounting for approximately 80% of the total, indicating a change in the investment landscape [15][16]. Group 4: Patience Capital - The concept of "patience capital" is crucial in the current investment environment, where both GPs and LPs must cultivate trust and understanding to foster long-term relationships [21][22]. - The need for patience is particularly relevant in the context of technology innovation and early-stage investments, which require time to mature and yield returns [24][25]. - Effective communication and transparency between GPs and LPs are essential for building trust and ensuring that both parties can navigate the uncertainties of the market together [23][24].

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

股票代码：600120 证券简称：浙江东方 编号：2025-033 债券代码：138898.SH 债券简称：23 东方 01 债券代码：240620.SH 债券简称：24 东方 01 债券代码：241264.SH 债券简称：24 东方 K1 债券代码：241781.SH 债券简称：24 东方 03 浙江东方金融控股集团股份有限公司 关于全资子公司拟出资设立股权投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟设基金名称：东方象山高质量发展合伙企业（有限合伙）（暂定名，以下 简称"象山基金"，最终名称以注册地市场监督管理局核定名为准）。 投资金额：公司全资子公司浙江东方集团产融投资有限公司（以下简称"东 方产融"）拟作为基金管理人发起设立象山基金，东方产融指定主体拟作为有限 合伙人认缴出资1.74亿元，东方产融全资子公司产融产投（杭州）股权投资有限 公司（以下简称"产融产投"）作为执行事务合伙人认缴出资100万元。 本次交易未构成关联交易，不构成重大资产重组。 风险提示：象山基金依法设立后，后续能 ...

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan for the fiscal year 2024, which was approved at the annual shareholders' meeting on May 22, 2025 [1][2]. Dividend Distribution Plan - The total share capital for the dividend distribution is 3,415,381,492 shares, from which 68,325,601 shares held in the repurchase account will be excluded, resulting in a base of 3,347,055,891 shares for the cash dividend distribution [2][3]. - A cash dividend of 0.84 RMB per 10 shares (including tax) will be distributed, totaling approximately 281,152,694.84 RMB (including tax) [2][3]. - The actual cash dividend per share, after accounting for the shares not participating in the distribution, is approximately 0.0823 RMB per share [3]. Relevant Dates - The record date for the dividend distribution is June 19, 2025, with the last trading day on June 20, 2025, and the ex-dividend date also on June 20, 2025 [1][3]. Implementation of Distribution - The cash dividends for unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [3][4]. - Shareholders who have not completed designated trading will have their dividends held by the China Securities Depository and Clearing Corporation until they complete the necessary trading [3]. Taxation on Dividends - For individual shareholders, the actual cash dividend after tax will be 0.084 RMB per share, with tax implications based on the holding period [6]. - For qualified foreign institutional investors (QFIIs), the net cash dividend after a 10% withholding tax will be 0.0756 RMB per share [7]. - Other institutional investors will not have taxes withheld by the company, and the cash dividend will remain at 0.084 RMB per share [8].

下 天册律师事务所 下 下 & C L A W F I R M 法律意见书 浙江天册律师事务所 关于 浙江东方金融控股集团股份有限公司 2024 年度差异化分红事项的 法律意见书 天册律师事务所 T & C LAW FIRM 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话: 0571-87901111 传真: 0571-87901500 下 天册律师事务所 法律意见书 浙江天册律师事务所 关于浙江东方金融控股集团股份有限公司 2024年度差异化分红事项的 法律意见书 编号:TCYJS2025H0868 致:浙江东方金融控股集团股份有限公司 浙江天册律师事务所 (特殊普通合伙)(以下简称"本所"或"天册") 接受浙 江东方金融控股集团股份有限公司(以下简称"浙江东方"、"公司"或"上市公司") 的委托,根据《中华人民共和国公司法(2023 修订)》(以下简称"《公司法》")、 《中华人民共和国证券法 (2019修订)》(以下简称"《证券法》")、《上市公司 股份回购规则(2025 修订)》(以下简称"《回购规则》")、《上海证券交易所上 市公司自律监管指引第7号 -- 回购股份(2 ...

浙江东方金融控股集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.084元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 是 | 证券代码：600120 | 证券简称：浙江东方 | | | 公告编号：2025-032 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | ...

| 股票代码：600120 | 证券简称：浙江东方 | | | 编号：2025-031 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 06 月 12 日 前 访 问 网 址 https://eseb.cn/1oQSv0vb02I 或使用微信扫描下方小程序码进行会前提问，公司将通 过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 一、说明会类 ...

| 股票代码：600120 | 证券简称：浙江东方 | | | 编号：2025-030 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于为下属公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 被担保人名称： 1、东方嘉富人寿保险有限公司（简称"东方嘉富人寿"，原名中韩人寿保 险有限公司） 2、浙江济海贸易发展有限公司（简称"浙江济海"） ● 逾期担保数量：公司不存在逾期担保情况，也不存在到期债务未清偿要求 公司承担担保责任情况。 ● 风险提示：本次被担保人中，东方嘉富人寿、浙江济海、东方供应链、舟 山济海、济桐贸易的资产负 ...